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The interplay Between Monocytes/
Macrophages and CD4+ T Cell 
Subsets in Rheumatoid Arthritis
Ceri A. Roberts , Abigail K. Dickinson and Leonie S. Taams*
Centre for Molecular and Cellular Biology of Inflammation (CMCBI), Division of Immunology, Infection and Inflammatory 
Disease, King’s College London, London, UK
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by inflammation 
of the synovial lining (synovitis). The inflammation in the RA joint is associated with and 
driven by immune cell infiltration, synovial hyperproliferation, and excessive production 
of proinflammatory mediators, such as tumor necrosis factor α (TNFα), interferon γ (IFNγ), 
interleukin (IL)-1β, IL-6, and IL-17, eventually resulting in damage to the cartilage and 
underlying bone. The RA joint harbors a wide range of immune cell types, including 
monocytes, macrophages, and CD4+ T cells (both proinflammatory and regulatory). The 
interplay between CD14+ myeloid cells and CD4+ T cells can significantly influence CD4+ 
T cell function, and conversely, effector vs. regulatory CD4+ T cell subsets can exert 
profound effects on monocyte/macrophage function. In this review, we will discuss how 
the interplay between CD4+ T cells and monocytes/macrophages may contribute to the 
immunopathology of RA.
Keywords: rheumatoid arthritis, inflammation, immune regulation, cell polarization, myeloid cell, T helper cell, 
Treg
RHeUMATOiD ARTHRiTiS
Rheumatoid arthritis (RA) is a chronic inflammatory and debilitating disease, characterized by 
inflammation of the lining of the joint (synovitis), eventually leading to the destruction of cartilage 
and the underlying bone. RA affects between 0.5 and 1% of the Western adult population with a 
female:male ratio of 3:1. The exact etiology of RA is still unknown, but it is widely accepted that RA 
is a multifactorial disease with genetic, environmental (e.g., smoking), gender and age-associated 
factors contributing to the disease process (1–3).
Typical hallmarks of RA are pannus formation and synovial hyperplasia, caused by proliferating 
fibroblasts and infiltrating immune cells. These events promote leukocyte recruitment, immune cell 
activation, and production of inflammatory mediators and proteinases, all of which eventually con-
tribute to joint damage. A wide range of immune cells has been detected in the RA joint, including 
CD4+ T cells, CD8+ T cells, B cells, NK cells, γδ T cells, mast cells and myeloid cells. Various soluble 
mediators produced by these immune cells have been shown to correlate with disease progression 
and/or severity in RA, e.g., rheumatoid factor, anti-citrullinated peptide antibodies, tumor necrosis 
factor (TNF)α, interleukin (IL)-6, IL-1, and IL-17A (2, 4). The importance of the immune system in 
disease pathogenesis is illustrated by the recent success of biologic therapies that target key inflam-
matory cytokines (e.g., TNFα blockade and anti-IL-6R therapy), immune molecules (e.g., CTLA4-Ig 
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leading to blockade of CD80/CD86-mediated costimulation), 
and immune cells (e.g., B cell depletion).
MONOCYTeS AND MACROPHAGeS iN 
RHeUMATOiD ARTHRiTiS
Monocytes/macrophages are a potent source of proinflammatory 
cytokines, in particular TNFα, IL-6 and IL-1, and matrix metal-
loproteinases (MMPs), leading to endothelial cell activation, 
acute phase reactions, and cartilage damage. These cells can also 
produce a wide range of chemokines, which help recruit addi-
tional leukocytes to the inflamed joint. In addition, monocytes 
have the ability to polarize CD4+ T cells and can differentiate 
into osteoclasts, which may further contribute to their role in RA 
pathogenesis. As such, monocytes and macrophages are viewed 
as relevant therapeutic targets in RA (5–7).
Myeloid cells with a monocyte/macrophage phenotype (i.e., 
CD14+CD68+) are present in large numbers in the rheumatoid 
joint. Several studies have shown that these cells produce pro-
inflammatory cytokines (8, 9) and have an activated phenotype 
with increased expression of HLA-DR (involved in antigen pres-
entation to CD4+ T cells), costimulatory molecules (e.g., CD80, 
CD86, and CD40), adhesion molecules (e.g., CD54), and some 
chemokine receptors (10–18). The importance of synovial CD68+ 
macrophages in RA pathogenesis is underlined by the findings 
that the presence of these cells correlates with disease activity 
markers (19, 20) and that a change in their presence has been 
reported to be a reliable biomarker for response to treatment (21). 
An early, small study in patients with RA (n = 10) noted that syno-
vial CD68+ cells were reduced in the perivascular and connective 
tissue areas 12  weeks after treatment with gold (22). Sublining 
macrophage count was also shown to correlate significantly 
with radiologic outcome and radiologic progression in patients 
with RA (n = 23–27) (20). An elegant study by Haringman et al. 
investigating arthroscopic synovial tissue biopsies from patients 
with RA (n = 88) participating in various clinical trials, showed 
that a reduction in the number of synovial sublining CD68+ 
macrophages correlated significantly with clinical improvement 
independently of the therapeutic strategy (23). Importantly, the 
number of sublining macrophages did not change after placebo or 
ineffective treatment, supporting its use as a predictive biomarker 
for response to treatment (21, 23).
A growing number of studies have reported on the frequen-
cies and phenotype of peripheral blood monocyte subsets in 
RA. Phenotypically, peripheral CD14+ monocytes in patients 
with RA show some signs of altered activation with studies 
reporting increased expression of CD14, FcγRs, CD54, CD11b, 
and/or HLA-DR (18, 24–27), although not all studies agree 
on increased HLA-DR expression (24, 27). Peripheral blood 
monocytes from RA patients are also reported to express 
increased levels of transmembrane TNF (tmTNF) (28). Human 
monocytes can be divided into subpopulations based on expres-
sion of CD14 [lipopolysaccharide (LPS) coreceptor] and CD16 
(FcγRIII). CD14++CD16− “classical” monocytes are the most 
prevalent subset, representing ~90% of blood monocytes in 
healthy individuals. CD16-expressing cells are less frequent 
among circulating monocytes but are expanded in infection and 
inflammatory conditions (29). CD16+ monocytes can be further 
subdivided into CD14++/bright (also called “intermediate”) and 
CD14dim (“non-classical” or “patrolling”) subsets (29, 30). Earlier 
studies, which did not necessarily discriminate between CD14++/
brightCD16+ and CD14dimCD16+ cells, showed an increase in the 
percentage of CD14+CD16+ monocytes in RA blood (31–33). 
CD14+CD16+ monocytes in RA express high levels of CCR1, 
CCR5, ICAM-1, or TLR2 (27, 32, 33). Higher frequencies of 
CD14+CD16+ blood monocytes were associated with clinical 
parameters of active disease (31, 33). More recent data suggest 
that only the frequency of CD14++/brightCD16+ intermediate cells 
is increased in peripheral blood of patients with chronic RA 
compared to sex- and age-matched healthy donors, while the 
frequency of non-classical CD14dimCD16+ monocytes does not 
differ between patients and controls (27, 34, 35). The frequency 
of CD14++/brightCD16+ cells at baseline was found to negatively 
correlate with response to methotrexate treatment (34). However, 
another study reported, using absolute cell counts, that both 
CD14++/brightCD16+ and CD14dimCD16+ monocyte populations 
are increased in RA blood (36). Ligation of CD16 using immune 
complexes or FcγRIII-specific mAb enhances proinflammatory 
TNFα production, suggesting that the expression of CD16 could 
be functional (32, 34, 37).
Recently, Krasselt et  al. showed that CD14brightCD56+ 
monocytes, which are predominantly composed of classical 
CD14brightCD16− cells, produce more TNFα, IL-10, and IL-23 
in response to LPS and demonstrate increased spontaneous 
production of reactive oxygen intermediates [reactive oxygen 
species (ROS)] compared to CD14brightCD56− monocytes (38). 
CD14brightCD56+ frequencies were positively correlated with 
age in healthy controls and were expanded in the blood of 
young RA patients compared to age-matched healthy controls. 
The CD14brightCD56+ subpopulation was reduced in a longitu-
dinal study of 16 RA patients following anti-TNF treatment. 
Additional studies are required to further elucidate the role of 
CD14brightCD56+ monocytes in RA.
In RA synovial fluid, it appears to be the intermediate 
CD14++/brightCD16+ monocyte population that is increased in 
frequency compared to matched peripheral blood (31, 33, 35). 
One explanation for the increased frequency of CD16 expressing 
synovial monocytes is that there is a specific expansion of the 
CD14++/brightCD16+ monocyte population. Another non-mutually 
exclusive explanation is that there is de novo expression of CD16 
triggered by the inflammatory milieu. It was shown that in vitro 
stimulation of healthy monocytes with recombinant transform-
ing growth factor β (TGFβ) or RA synovial fluid induced elevated 
CD16 expression, an effect that was inhibited by TGFβ signaling 
blockade (35).
Table 1 summarizes the reported phenotypic features of CD14+ 
cells derived from RA peripheral blood or synovial fluid, and 
cells with a macrophage phenotype in synovial tissue. It should 
be noted that studies on synovial fluid or synovial tissue gener-
ally involve the whole CD14+ and/or CD68+ population (which 
may contain monocytes and macrophages), rather than sorted 
subsets. Therefore, Table  1 represents a summary of relevant 
literature reports on monocyte/macrophage cell phenotypes 
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within different anatomical compartments rather than a direct 
comparison of these cells between different compartments.
eFFeCT OF MONOCYTeS/
MACROPHAGeS ON CD4+ T CeLL 
SUBSeTS
In addition to the innate effector functions of monocytes/mac-
rophages in terms of proinflammatory cytokine and chemokine 
production, their inflammatory role in RA pathogenesis may 
stem from their function as a bridge to the adaptive immune 
system. Colocalization of CD14+ cells with clusters of CD4+ 
effector T cells at sites of inflammation has been reported in 
inflamed rheumatoid synovium, as well as in inflamed tonsil, and 
psoriatic or atopic dermatitis skin (41, 42), suggesting that CD4+ 
T cells and monocytes/macrophages can interact in vivo at sites 
of inflammation.
CD4+ T Helper Cell Polarization by 
Monocytes/Macrophages
Dendritic cells (DCs) are classically considered to be the major 
drivers of CD4+ T helper cell polarization; however, evidence is 
accumulating that monocytes/macrophages can also play a role 
in this process. Monocytes and/or macrophages can be major 
sources of IL-1β, IL-6, IL-12, and IL-23, cytokines known to be 
present in the RA joint (4, 8, 9, 43, 44). IL-12 is involved in driv-
ing CD4+ T helper 1 (Th1) cell polarization, while IL-1β, IL-6, 
and IL-23 can drive and maintain Th17 polarization. Interferon 
γ (IFNγ)+CD4+ T cells (indicative of Th1 cells) and IL-17+ 
CD4+ T cells (indicative of Th17 cells) are readily detectable in 
the RA joint, in both the tissue and the fluid (45–47). Th1 cells 
TABLe 1 | Phenotypic features of monocytes/macrophages from RA 
peripheral blood, synovial fluid, and synovial tissue.
Compartment Phenotype Reference
(a) Peripheral 
blood
↑ HLA-DR, CD14, CD40, CD54, CD11b
↑ Fcγ receptors (including CD16)
(18, 24–26)
(18, 24, 26, 27, 
31–36)
↑ CCR3, CCR4, CCR5 (15)
↑ tmTNFα (28)
↑ Spontaneous IL-1β production (25, 28)
↑ Resistance to apoptosis (28, 39)
(b) Synovial 
fluid
↑ HLA-DR, CD40, CD54, CD80, CD86, CD276 (11, 13, 14, 
16–18, 35)
↑ CD16+ (18, 31, 33, 35)
↓ CCR1, CCR2, CCR4, ↑CCR3, CCR5 (15)
↑ Resistance to apoptosis (39, 40)
(c) Synovial 
tissue
HLA-DR+
CD68+
(10, 14)
(15, 19–23)
CD163+ (12)
IL-1+, TNFα+, IL-6+, GM-CSF+, TGFβ+ (8, 9, 14)
Arrows indicate phenotypic alterations observed in CD14+ cells from the peripheral 
blood of rheumatoid arthritis (RA) patients in comparison to healthy donor peripheral 
blood CD14+ cells (a), or in CD14+ cells from RA synovial fluid compared to RA 
peripheral blood CD14+ cells (b). Phenotypic markers that are expressed on cells with a 
macrophage phenotype from RA synovial tissue (c).
were originally thought to be one of the major contributors in 
RA pathogenesis, based on their abundance in RA synovial 
fluid, their key role in certain experimental models of arthritis, 
as well as the inflammatory function of IFNγ particularly on 
macrophage activation. However, studies have shown that IFNγ 
may also have a protective, rather than an exacerbating role in 
RA (48–50), which may be due to its antagonistic effects on Th17 
induction (51) or on VEGF production (46, 52), thereby possibly 
inhibiting angiogenesis.
In recent years, IL-17 and Th17 cells have gained attention as 
critical mediators in RA pathogenesis. IL-17 is a potent proin-
flammatory cytokine that works in synergy with TNFα to induce 
the inflammatory events and joint damage that are characteristic 
of RA (53, 54). The receptors for IL-17 (IL-17RA and IL-17RC) 
are expressed in RA synovium, including on CD14+ monocytes/
macrophages (55) and stimulation of RA synovium with IL-17 
leads to production of IL-6, MMPs, and joint degradation (56–58). 
Blood CD14+ monocytes can be potent inducers of human Th17 
responses depending on their activation status. Human blood 
monocytes activated by peptidoglycan or LPS were shown to 
efficiently promote Th17 responses from cocultured naive CD4+ 
T cells in the presence of anti-CD3 mAb (59). Our own lab found 
that following in vitro activation with LPS, peripheral blood CD14+ 
monocytes from either healthy donors or RA patients promoted 
Th17 responses in an IL-1β- and TNFα-dependent manner (17, 
60). It was also shown that human monocytes stimulated in vitro 
with heat-killed pneumococci triggered a Th17 response which 
was dependent on TLR2 signaling (61). In contrast, stimulation 
with live pneumococci led to a mixed Th1/Th17 response due to 
monocyte production of IL-12p40. In a non-infectious setting, 
peripheral blood monocytes from patients with type 1 diabetes 
spontaneously secreted the proinflammatory cytokines IL-1β 
and IL-6. These cells induced higher frequencies of Th17 cells 
from memory T cells in  vitro compared with monocytes from 
healthy control subjects, which was reduced by a combination of 
an IL-6-blocking Ab and IL-1R antagonist (62). Finally, healthy 
peripheral blood monocytes that were treated with RA synovial 
fluid prior to coculture with anti-CD3/CD28-stimulated CD4+ 
T cells were shown to promote Th17 differentiation, which was 
attributed to a TNFα-mediated increase in monocytic production 
of IL-6 and IL-1β (63).
Additional studies in mice and human show that monocytes/
macrophages from the synovial fluid of the inflamed arthritic 
joint, which may contain extravasated monocytes as well as 
tissue-resident macrophages, can promote IL-17 production in 
CD4+ T cells (17, 35, 64). These data suggest that newly recruited 
CD4+ T cells in the rheumatoid joint might be steered toward a 
Th17 response by local monocytes/macrophages. The ensuing 
positive feedback loop between Th17 cells and monocytes/
macrophages may then perpetuate inflammation (42). In our 
own work, the induction of Th17 responses by in vivo activated 
monocytes isolated from RA synovial fluid was found to be 
independent of TNFα, IL-1β, IL-6, and IL-23, and to involve cell 
contact (17). In line with our observations, Yoon et  al. found 
increased Th17 responses when stimulated autologous peripheral 
blood memory CD4+ T cells were cocultured with RA synovial 
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fluid monocytes, compared to responses elicited by circulating 
monocytes. In contrast to our finding that Th1 polarization was 
not strongly affected by the anatomical origin of monocytes (17), 
Yoon et al. found that intracellular IFNγ expression (and in most 
donors tested, the level of IFNγ in culture supernatants), was also 
significantly increased by coculture with synovial monocytes 
compared to blood monocytes (35). Thus, synovial monocytes/
macrophages may promote both Th17 and Th1 responses.
It is currently unclear whether the capacity of monocytes 
to promote Th17 responses resides in a particular monocyte 
subset. Rossol et al. found that circulating intermediate CD14++/
brightCD16+ monocytes in the presence of LPS promoted Th17 
cell expansion from peripheral blood memory CD4+ T cells 
in vitro, and that the frequency of CD14++/brightCD16+ monocytes 
in peripheral blood of RA patients correlated closely with ex 
vivo Th17 cell frequencies (27). Traunecker et al. reported that 
non-classical (CD14dimCD16+) monocytes from healthy donors 
when cocultured with autologous CD4+ T cells and specific supe-
rantigens in the absence of pathogen-recognition receptor (PRR) 
stimuli were more efficient stimulators of IL-17-producing T cells; 
however, in the presence of PRR stimuli, Th17 expansion was 
mostly observed in cocultures with classical (CD14++/brightCD16−) 
or intermediate (CD14++/brightCD16+) monocytes (65). Blocking 
of LFA-1/ICAM-1 interaction increased the frequency of IL-17-
producing T cells expanded from non-classical monocyte/CD4+ 
T cell/superantigen cocultures. However, no significant differ-
ences in capacity to promote Th17 responses were observed in 
experiments assessing peripheral blood monocyte subsets from 
11 RA patients. In contrast to the above studies, Smeekens et al. 
found that only CD14++/brightCD16− classical monocytes and 
not CD16+ monocytes could induce a protective Th17 response 
in response to Candida albicans, due to increased IL-1β and 
prostaglandin E2 production (66). It is crucial to achieve high 
degree purity separation for functional characterization of cell 
subpopulations and the use of magnetic bead separation to isolate 
CD16+ vs. CD16− monocytes rather than high purity FACS-based 
cell sorting in the study by Smeekens et al. may therefore limit 
interpretation of the results. Nonetheless, a recent study by Liu 
et al. also found that after coculturing autologous memory CD4+ 
T cells with FACS-purified monocyte subsets and anti-CD3, 
classical CD14++/brightCD16− monocytes most potently expanded 
IL-17+ memory CD4+ T cells (67). Non-classical CD14+CD16++ 
monocytes were the strongest inducers of IFNγ expression in 
naive CD4+ T cell cocultures. The above in  vitro experiments 
employ different modes of T cell activation with or without PRR 
stimulation of monocytes, which may contribute to the heteroge-
neity of the results obtained. Activation of T cells via crosslink-
ing of soluble anti-CD3 (67) triggers MHC-independent T cell 
activation, whereas stimulation via superantigen (65) crosslinks 
MHC on monocytes and TCR on T cells, more closely represent-
ing an MHC-restricted antigen-specific stimulation. Altering the 
activation state of monocyte subsets via PRR agonists (27, 65, 
66) may also affect their capacity to polarize CD4+ T cells. Any 
conclusions drawn from these and future studies regarding the 
contribution of different monocyte subsets to CD4+ T cell polari-
zation should take into account the choice of in vitro stimulation 
and ideally should be confirmed in multiple systems.
Monocytes/macrophages are also a major source of IL-15 
(68), a pleiotropic cytokine which mediates several important 
proinflammatory effects on both monocytes/macrophages and 
CD4+ T cells. The IL-15Rα is overexpressed on blood-derived 
lymphocytes and monocytes in RA patients (69), and IL-15 is 
found at high levels in RA SF (70). IL-15 plays an important role 
in regulating T cell migration and was shown in vivo to facilitate 
accumulation of adoptively transferred T cells in RA synovial tis-
sues engrafted into immune deficient SCID mice (71). IL-15 also 
promotes TNFα production by synovial T cells (72), and IL-15-
activated blood-derived or synovial T cells can induce TNFα in 
a macrophage cell line and in RA blood- or synovium-derived 
monocytes/macrophages in a cell-contact-dependent manner 
(72). IL-15 may also promote IL-17 production by synovial T cells 
(73), although in mice a fine-tuning effect of IL-15 on Th17 dif-
ferentiation was reported (74). IL-18 is another proinflammatory 
cytokine expressed in RA synovium, most prominently in CD68+ 
macrophages (75). IL-18 acts in synergy with other cytokines, 
including IL-12 and IL-15, to stimulate T cell production of IFNγ 
and synovial macrophage release of TNFα (75). In the RA joint, 
IL-18 also acts as a chemoattractant for synovial CD4+ T cells (76) 
and monocytes (77). Together, these data indicate that produc-
tion of IL-15 and IL-18 by monocytes and/or macrophages may 
also be relevant in driving or polarizing inflammatory CD4+ T 
cell responses in the RA joint.
In addition to their role as antigen-presenting and cytokine-
producing cells, macrophages can efficiently generate ROS, an 
important antimicrobial defense mechanism that occurs via 
activation of the phagocytic NADPH oxidase complex. Rats and 
mice with genetic variation in the neutrophil cytosolic factor Ncf1 
(encoding p47phox, an activating protein in this complex) dem-
onstrate reduced capacity to exert oxidative burst and increased 
incidence and severity of T cell-dependent arthritis (78, 79). When 
efficient ROS production was restored specifically in macrophages, 
T cell-dependent arthritis development was ameliorated (80). 
In vitro, T cells from mice lacking functional macrophage Ncf1 
demonstrated increased proliferation and cytokine production in 
response to antigenic stimulation, as compared to T cells from 
mice with ROS-competent macrophages. Coculturing T cells 
from ROS-deficient mice with ROS-competent macrophages led 
to suppressed T cell IL-2 production and proliferative responses 
to antigen, suggesting that macrophage ROS production affects 
antigen presentation in  vitro. However, irrespective of whether 
macrophages used in the coculture could produce ROS, IFNγ 
production was increased when CD4+ T cells were derived 
from ROS-deficient mice, indicating that in  vivo exposure to 
macrophage ROS production may suppress Th1 responses. In 
agreement with these findings, King et al. found that human T 
cells stimulated with anti-CD3/CD28 in the presence of ROS 
demonstrated an increase in type 2 cytokines with no alteration 
in type 1 cytokine production, even in culture conditions polar-
izing toward a Th1 phenotype, and which could be reversed by 
concomitant antioxidant exposure (81). Together, these findings 
suggest that ROS production by macrophages may have the 
potential to downregulate or modulate T helper cell responses.
It is well known that certain inbred mouse strains show a bias 
toward either Th1 or Th2 responses, e.g., C57BL/6 and BALB/c, 
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respectively. The bias in Th1- or Th2-like cytokine profiles is 
maintained in NUDE or SCID mice lacking an adaptive immune 
system, suggesting a role for the innate immune system in driving 
this polarization and giving rise to the concept of M1 and M2 
macrophages (82). Studies of transgenic (Tg) mice have provided 
in vivo evidence that inflammatory macrophage subpopulations 
can polarize CD4+ T cell responses in mouse models of arthritis. Li 
et al. crossed a Floxed STOP-human/mouse DR5 Tg mouse with the 
LysM.Cre mouse, to express the Tg human/mouse-chimeric death 
receptor 5 (DR5) restrictively in myeloid lineage cells. Treatment 
of these mice with an antihuman DR5 agonistic antibody led to 
targeted depletion of CD11bhighLy6C+ inflammatory macrophages 
and reduced development and severity of collagen-induced 
arthritis (83). Interestingly, the depletion of this macrophage 
subpopulation also significantly reduced protein levels of IL-6 and 
IL-17A in sera, reduced synovial Il17a, Il6, Tnfa, and Il23a(p19) 
mRNA expression and reduced the frequency of IL-17A+ and 
IFNγ+CD4+ T cells while increasing CD4+Foxp3+ cells in draining 
lymph nodes. These data support the notion that macrophages 
may be important contributors to CD4+ T cell polarization.
Dissecting the precise role of monocytes/macrophages in 
initiating adaptive immune responses can be challenging due to 
overlapping function and lineage marker expression with DCs. 
DCs are professional antigen-presenting cells that play a key 
role in promoting an effective immune response. A multitude 
of pattern recognition receptors allows DCs to sense invading 
pathogens and present both exogenous and endogenous antigens 
to naive and memory T cells. Different subsets of DC exist, 
including conventional or classical DC (cDC) type 1, cDC type 
2, plasmacytoid DC, and monocyte-derived DC (mo-DC). cDC 
develop independently from monocytes and originate from a 
common DC progenitor which expresses flt3 (84). It can be dif-
ficult to distinguish monocytes or macrophages from mo-DCs 
or cDC type 2, due to overlap in certain markers (e.g., CD14, 
CD11b, CD11c, and CX3CR1) (85). CD64 has been identified 
as a marker that can be used to distinguish mo-DCs from cDCs 
in mice; however, these cells remain difficult to distinguish from 
cDCs in humans (86). Recently, researchers have taken a genetic 
approach to ablate monocytes and macrophages while sparing 
cDCs and lymphocytes by depleting M-CSF-R+LysM+ cells. 
Although neither monocytes nor macrophages were required 
to initiate immunity, when both cell types were depleted during 
infection with the intestinal pathogens Citrobacter rodentium 
or Listeria monocytogenes, IFNγ+CD4+ T cells were reduced in 
the lamina propria, demonstrating the capacity of monocytes/
macrophages to influence T cell polarization (87). In contrast, 
the IL-17 response was not altered by monocyte and macrophage 
depletion but was significantly impaired upon selective depletion 
of cDCs, indicating that this cell population is necessary for 
mucosal Th17 responses. Macrophage depletion has also been 
shown to reduce type 2-dependent immune responses in the 
lung and gut. Depletion of CD11b+ F4/80+ macrophages led to a 
significant reduction in recruitment and cytokine expression of 
Th2 cells in affected tissues of three models of IL-13-dependent 
inflammation, fibrosis, and immunity, without any such reduc-
tion in the draining lymph nodes (88). Since CD11b+ DCs might 
also be susceptible to depletion, studies of CD11c-DTR and 
CD11b/c-DTR double Tg mice confirmed that macrophages 
but not CD11c+ DCs were critical for the maintenance of type 
2-dependent responses. Reduced expression of the Th2 cell che-
moattractants CCL1 and CCL22 may be one mechanism through 
which Th2 cell recruitment is impaired in a Schistosoma mansoni 
egg-induced lung granuloma model following macrophage 
depletion (88). Macrophage production of the chemokine CCL5 
was recently shown to be important for the maintenance of stable 
tissue-resident memory IFNγ-producing CD4+ T cell (TRM) 
populations in memory lymphocyte clusters in a mouse model 
of genital herpes (89). Further studies are needed to investigate 
the presence of TRM in RA synovial tissue and the requirement for 
monocytes/macrophages in maintaining these populations.
T Helper Cell Recruitment by Monocytes/
Macrophages
As alluded to the previous section, monocytes/macrophages 
can play an important role in recruiting or maintaining CD4+ T 
cells in the arthritic joint. The C–X–C motif chemokine receptor 
CXCR6+ is abundantly expressed on type 1 polarized effector 
memory T cells in RA synovial fluid (90, 91). Expression of 
CXCR6 on synovial T cells is reported to coincide with elevated 
expression of CXCL16 (the ligand for CXCR6) by synovial mac-
rophages, endothelial cells, and fibroblast-like synoviocytes (FLS) 
in hypertrophic RA synovium (90). Significantly increased levels 
of cleaved CXCL16 have been demonstrated in RA SF compared 
to control samples (90, 92), and RA synovial tissue macrophages 
express both CXCL16 and CXCR6 (92). In vitro migration experi-
ments demonstrate that healthy PBMC or CXCR6+ T cells iso-
lated from RA SF can migrate in response to exogenous CXCL16 
or CXCL16 present in SF (90, 92). Together, these data suggest 
that increased CXCL16 expression in RA synovium, either due 
to increased expression by macrophages (90) or due to increased 
influx of monocytes (93), promotes recruitment of CXCR6+ T 
cells and may thereby contribute to synovial inflammation and 
immunopathology. CXCL16 expression can be differentially 
regulated by cytokines: the Th2-like cytokines IL-4, IL-10, and 
IL-13 suppress secretion of CXCL16 by monocytes/macrophages, 
while the Th1-associated cytokine IFNγ slightly enhances 
CXCL16 secretion (93). No modulation of CXCL16 levels was 
observed upon addition of IL-15, IL-18, or TNFα to monocytes/
macrophages. In contrast, earlier work found that exposure of 
monocytes to TNFα upregulated transmembrane expression and 
secretion of CXCL16 (90) suggesting that a reduction in synovial 
TNFα levels might impact on recruitment of CXCR6+ T cells to 
the joint. In a small study of three patients responding to anti-
TNF treatment, in  situ immunohistochemistry demonstrated 
significantly reduced synovial CXCL16 expression compared 
to the high expression levels observed pretreatment (90). This 
observation may be due to reduced monocyte numbers in the 
joint following treatment, since synovial cellularity is known to 
be reduced soon after anti-TNF infusion (94–96). Conversely, 
in three non-responder patients, CXCL16 expression remained 
high. In accordance with reduced CXCL16 expression in the joint 
following successful anti-TNF therapy, serum levels of CXCL16 
were also decreased after anti-TNF treatment in two cohorts 
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of 23 and 44 RA patients, respectively (97, 98). Thus far, these 
studies suggest that monocyte infiltration and/or type 1 cytokine 
production in the RA joint may enhance local production of 
soluble CXCL16, which may exacerbate local inflammation via 
recruitment of CXCR6+ T cells.
Another chemokine receptor interaction of increasing inter-
est in RA is the C–C chemokine ligand CCL20 [also known as 
macrophage inflammatory protein-3 alpha (MIP-3α)] and its 
C–C chemokine receptor CCR6 [recently reviewed in Ref. (99)]. 
CCR6 expression is commonly associated with Th17 cells (100), 
but this receptor is also expressed on memory T cells (101), 
including CD4+ T cells expressing IFNγ with or without IL-17 
(102), as well as DC, B cells, and regulatory T cell (Treg) (99). In 
the SKG mouse model of T cell-mediated autoimmune arthritis, 
the CCL20–CCR6 axis is implicated in recruiting Th17 cells to 
the joint, via spontaneous CCL20 production from adherent FLS 
(103). The authors found that dispersed monocytes from mouse 
synovial tissue did not produce CCL20 unless stimulated. Others 
found that unstimulated FLS from RA patients did not produce 
CCL20, but that stimulation with either IL-1β or TNFα led to 
the production of CCL20 at levels sufficient to promote CCR6-
specific recruitment of mononuclear cells, and which could 
be increased by IL-17 and decreased by IL-4 (104). In patients 
with juvenile idiopathic arthritis, CCL20 mRNA was shown to 
be constitutively expressed by synovial monocytic cells (105). 
In addition, in  vitro exposure to plasmin, a component of the 
fibrinolytic cascade which is generated in inflamed tissues, can 
trigger production of CCL20 by human macrophages and lead 
to chemotactic migration of CCR6+ Th17 cells in vitro (106). A 
role for plasmin in RA has been suggested by observations from 
collagen-induced arthritis (107) but has yet to be confirmed 
in the human setting. In summary, there is a potential role for 
monocytes in influencing the CCL20–CCR6 axis in RA.
Modulation of CD4+ Treg Function by 
Monocytes/Macrophages
In addition to effects on T helper cell polarization, activated 
monocytes and macrophages can also positively or negatively 
influence the function of CD4+ Tregs through production of 
soluble mediators. IL-1β has been shown by several groups to 
drive IL-17 expression by CD4+CD25+ Tregs [reviewed in Ref. 
(108)]. Excessive production of IL-6 in  vivo inhibited induc-
ible Treg generation from naive T cells but did not affect the 
development and function of natural Tregs (109). A recent study 
showed that IL-6 negatively affected FOXP3 protein expression 
by reducing expression of USP7 and disrupting USP7–FOXP3 
association. USP7 is a deubiquitinase that prevents proteasomal 
degradation of FOXP3, thereby increasing FOXP3 expression 
levels and enhancing Treg function (110). TNFα has also been 
shown to decrease FOXP3 expression and reduce Treg function 
(111, 112). Additionally, anti-TNF therapy was shown to induce 
the differentiation of a suppressive CD4+CD25hiFOXP3+CD62L− 
Treg subpopulation through conversion of CD4+CD25− T cells in 
RA patients (113).
Contrastingly, TNFα has also been shown to boost Treg expan-
sion and/or function (114, 115). Our lab recently showed that 
monocytes, activated in vitro with LPS or with cytokines known 
to be present in the RA joint, can induce expression of proin-
flammatory cytokines (IL-17 and IFNγ) in CD4+CD25+CD127low 
Tregs in an IL-6-, TNFα-, and IL-1β-dependent manner (18). 
However, despite the increase in proinflammatory cytokine 
expression, these Tregs maintained and even enhanced their sup-
pressive capacity, indicating that acquisition of proinflammatory 
cytokine expression does not necessarily imply loss of suppressive 
function (18). Conversely, it has been shown that TNFα and IL-6 
can alter the susceptibility of effector T cells to Treg-mediated 
regulation, making them resistant to suppression (116–118).
Monocytes/macrophages can also boost Treg function directly 
by producing soluble mediators that are immunoregulatory in 
nature. A population of CD11b+F4/80+CD11c− macrophages has 
been identified in the lamina propria which can induce Foxp3+ 
Treg differentiation through a mechanism dependent on IL-10, 
retinoic acid, and TGFβ in the local milieu (119). As discussed 
above, macrophage-derived ROS might play a role in modulating 
effector T cell responses (80); however, it has also been sug-
gested that ROS can promote Treg-mediated immune regulation 
(120–122). Using both human and rat systems, macrophages were 
shown to suppress T cell responses by inducing FOXP3+ Tregs 
in a ROS-dependent manner (120). This was confirmed using 
macrophages from patients with chronic granulomatous disease 
(CGD) that are defective in ROS production; CGD macrophages 
allowed significantly more T cell activation and expansion and 
induced fewer FOXP3+ cells than did macrophages from control 
subjects. T cells primed by CGD macrophages showed reduced 
inhibition of responder T cell proliferation and IFNγ or IL-17 
production than did cells primed by control macrophages. Similar 
results were observed using rats with defective ROS production 
due to a SNP in Ncf1.
It was shown that monocyte subsets and their cytokines may 
have differential effects on subsets of Treg cells. In both humans 
and mice, ~70% of Tregs express the transcription factor Helios 
(123). CD16+ monocytes have been described to inhibit prolifera-
tion of Helios+ Tregs through a mechanism dependent on IL-12. 
In contrast, Tregs lacking Helios expression were suppressed by 
CD16− monocytes via TNFα, while TNFα blockade specifically 
expanded the Helios− Treg subset (124).
Figure 1 summarizes data from existing reports on the pro-
posed mechanisms via which monocytes/macrophages may affect 
the function of CD4+ effector vs. Tregs subsets. It should be noted 
that much of the reported evidence comes from in vitro studies, 
which indicate the potential involvement of these mechanisms 
but do not demonstrate conclusively if or where these events 
occur at the site of inflammation.
eFFeCTS OF CD4+ T CeLL SUBSeTS ON 
MONOCYTe/MACROPHAGe ACTivATiON 
AND FUNCTiON
Monocyte/Macrophage Activation and 
Polarization by CD4+ effector T Cells
Monocytes and macrophages are capable of responding to a 
wide range of stimuli and environmental cues, which in turn 
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can determine their phenotype. Macrophages can be polarized 
into diverse subtypes often termed M1 and M2; however, these 
phenotypes represent extremes on a spectrum of functional states 
(125). A recent transcriptomics study provided elegant evidence 
to support the latter concept (126). In this study, gene expression 
profiling was performed on 299 macrophage samples stimulated 
with 28 different conditions. Monocytes were differentiated into 
macrophages using either GM-CSF or M-CSF. The macrophages 
were subsequently activated using typical M1 (e.g., IFNγ, LPS, 
and TNF) or M2 (e.g., IL-4 and IL-13) stimuli, and standardized 
microarrays were performed. Analysis of the transcriptomes 
using coregulation analysis generated two groups of samples 
positioned at either end of a bimodal axis, representing M1/M2 
states. However, when the effect of other activation factors not 
associated with typical M1/M2 states was included in the analysis 
(e.g., high-density lipoprotein and free fatty acids), the spectrum 
expanded away from the axis to account for these dissimilar 
states. These data confirm that while it is possible to polarize 
macrophages into distinct M1/M2 populations, not all activators 
will generate populations that fit into or in between these states. 
It is therefore important to keep in mind that although in this 
review we refer to M1/M2 macrophages, a spectrum of activation 
outside of these phenotypes exists. Outside of stringent M1/M2 
phenotypes, it has become increasingly difficult to determine the 
exact nature of macrophages within published work. A recent 
review has highlighted a lack of coherently used markers used 
to define macrophage populations within the field (127). The 
authors discuss that incomplete descriptions of how macrophages 
have been isolated, stimulated, and analyzed can lead to confu-
sion between laboratories. Therefore, they propose a new nomen-
clature system, based on the macrophage activator and markers 
used to define the population. In this way, the anticipation is that 
we can better define and understand the distinct macrophage 
populations generated in different labs under different conditions 
and avoid confusion when attempting to place macrophages on a 
spectrum of activation.
Bearing in mind the limitations of the M1/M2 classification, 
cytokines that are typically associated with Th1 and Th2 cells have 
been used to polarize monocytes or macrophages in vitro with the 
Th1 cytokine IFNγ driving the M1 (classically activated) pheno-
type and the Th2 cytokines IL-4/IL-13 driving an M2 (alternatively 
activated) phenotype (128). Three further M2 subtypes have since 
been described; M2a, M2b, and M2c, all with different functional 
capabilities to those seen in an M1 phenotype (127, 129). M1 
macrophages typically release high levels of proinflammatory 
cytokines, such as IL-1, IL-6, IL-12, and TNFα, have high produc-
tion of reactive oxygen intermediates and metabolize arginine to 
nitric oxide. Typical M1 chemokines include CXCL5, CXCL8, 
CXCL9, CXCL10, and CXCL13. M2 macrophages are character-
ized by a switch in arginine metabolism from the iNOS pathway 
seen in M1 cells to the arginase pathway, releasing orthonine and 
polyamines. M2 cells release IL-10 and some IL-12 and express 
CD163, CD206, scavenger receptors A and B, and Dectin-1. M2 
macrophages are generally considered to be involved in wound 
healing and to promote tissue remodeling through release of 
growth factors VEGF and TGFβ (129, 130).
In addition to Th1 and Th2 cytokines, it has been shown 
that the Th17-associated cytokine IL-17A has direct effects on 
macrophages leading to an increase in IL-1β, TNFα, and IL-6 
(131, 132). Silencing of IL-17RA using siRNA reduced the 
upregulation of IL-1β, TNFα, and IL-6 by macrophages, thus 
showing that IL-17 signaling through IL-17RA can influence 
cytokine release of macrophages (132). IL-17 has been shown to 
be directly chemotactic for monocytes in vitro at concentrations 
found in RA synovial fluid, via ligation of IL-17RA and IL-17RC 
on monocytes and p38 MAPK activation (133). In vivo, human 
monocytes injected intravenously into SCID mice were recruited 
into subcutaneously implanted sponges which had been soaked 
with human IL-17 or the positive control CCL2 [also called 
monocyte chemoattractant protein-1 (MCP-1)] but not sponges 
soaked with IL-8 or IL-10 (133). Tissue-infiltrating Th17 cells 
(unlike Th1 and Th2 cells) also secrete CCL20 (45), which has 
been shown to be chemotactic for monocytes (134). IL-17 may 
also have indirect effects on monocyte chemotaxis through the 
induction of chemokine expression by other cell types present 
in the RA joint. In vitro addition of IL-17 to RA synovial fibro-
blasts or normal blood-derived macrophages effectively induced 
expression of CCL2 and CCL20 (135). However, in  vivo only 
CCL2 was secreted following adenovirus-mediated intraperito-
neal (i.p.) expression of IL-17. The increase in peritoneal CCL2 
FiGURe 1 | Proposed mechanisms via which monocytes/
macrophages in the inflamed RA joint can modulate CD4+ T cell 
responses. The arrow thickness reflects the evidence base to support the 
proposed mechanism. Monocyte/macrophage-derived cytokines, such as 
IL-1β, IL-6, TNFα, IL-12, IL-15, IL-18, and IL-23, are present in the RA joint 
(4, 8, 9, 43, 44, 70, 75). These cytokines can promote Th1 (IL-12, IL-15, and 
IL-18) and Th17 (IL-1β, IL-6, IL-15, IL-23, and TNFα) responses, and both 
Th1 and Th17 cells are detectable in synovial tissue and fluid (45–47). In vitro 
and in vivo data indicate that activated CD14+ blood monocytes or synovial 
monocytes/macrophages can potently induce Th17 (17, 35, 59–64) and/or 
Th1 (35, 61, 87) responses. Further studies are required to clarify whether 
different monocyte subsets preferentially promote specific Th responses. 
Activated monocytes/macrophages can also have profound effects on the 
phenotype and function of regulatory T cells (Tregs). Several groups have 
reported that IL-1β can drive IL-17 expression by CD4+CD25+ Tregs 
[reviewed in Ref. (108)], but these cells may retain suppressive capacity (18). 
Others have reported that TNFα and IL-6 lead to reduced FOXP3 expression 
in Tregs (110–112) or render effector T cells resistant to Treg-mediated 
suppression (116–118). Macrophage production of reactive oxygen species 
(ROS) may play a role in suppressing Th1 responses (80) and inducing 
FOXP3+ Tregs (120–122).
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levels contributed to increased monocyte recruitment, which 
was reduced by i.p. injection of neutralizing anti-CCL2 (135). 
Local IL-17 expression in ankle joints was also associated with 
increased F4/80 staining and CCL2 levels. The IL-17-mediated 
induction of CCL2 appeared to involve the PI3K, ERK, and (at 
least in RA synovial fibroblasts) JNK pathways.
There is good evidence that TCR- or cytokine-activated T 
cells can activate monocytes, resulting in inflammatory cytokine 
and MMP production by monocytes in a cell-contact-dependent 
manner (39, 136–138). The CD4+CD45RO+CCR7− effector 
memory T cell subset of cytokine-activated T cells has been sug-
gested to be a main driver of this stimulation (139). One study 
showed that distinct CD4+ T cell subsets (Th1, Th2, or Th17) may 
differentially affect monocyte differentiation into distinct mo-DC 
subsets in a cell-contact- and cytokine-dependent manner (42). 
Cocultures of sorted Th1, Th2, and Th17 cells with isolated CD14+ 
monocytes led to the generation of three distinct mo-DC subsets, 
as defined by typical DC markers. The monocytes cultured with 
Th1 cells formed DCs that secreted IL-12 and expressed CD86 
and CD274 (DCth1), whereas those generated through culture 
with Th2 cells expressed increased levels of IL-10, CD275, and 
DC-SIGN (DCth2). Monocytes cultured with Th17 cells devel-
oped into DCs that secreted IL-1β, IL-6, and IL-23 but not IL-12 
(DCth17). The DCs generated through coculture were then used 
as stimulators in a mixed leukocyte reaction; IFNγ and IL-17A 
were released from responding CD4+ T cells when cultured with 
DCth1 and DCth17, respectively. These data are in line with the 
results described above on how different Th-related cytokines 
affect macrophage polarization.
CD4+ T cells can also drive differentiation of monocytes into 
osteoclasts. Bone resorption by osteoclasts is of pathological 
significance in RA, causing “erosion sites” which can be used as a 
measure of disease severity and outcome. Studies have shown that 
IFNγ+ human T cells cultured with peripheral blood monocytes 
in the presence of M-CSF can induce osteoclast formation via 
expression of the cytokine receptor activator of NF-κB ligand 
(RANKL) (140). IFNγ may, however, also disrupt the formation 
of osteoclasts by rapidly degrading the RANK adaptor protein 
TRAF6 (141), suggesting that the IFNγ+ T cells can both contrib-
ute to and hinder the formation of osteoclasts. Th17 cells are often 
implicated in promoting osteoclastogenesis; Th17-associated 
cytokines were shown to upregulate RANKL on RA FLS and to 
directly induce monocyte-to-osteoclast differentiation (142, 143). 
In addition, RANKL-expressing Th17 cells were recently shown 
to convert mature osteoclasts to a bone resorptive state (144). T 
cells in the synovial fluid have been shown to express RANKL 
(145), and high levels of RANKL-expressing CD3+ cells have 
been found in the synovial tissue of patients with RA (146), thus 
potentially contributing to osteoclast formation and therefore 
higher levels of bone resorption.
Together, these data indicate that prototypical T helper cell-
associated cytokines can polarize, recruit, activate, or differenti-
ate monocytes and/or macrophages. In vivo, the phenotype and 
function of monocytes and macrophages is likely to be depend-
ent on many soluble factors and cellular interactions acting in 
concert.
induction of Apoptosis in Monocytes and 
Macrophages by CD4+ T Cells
In addition to activating monocytes or macrophages, several 
reports have shown that activated CD4+ T cells can kill these 
cells (147, 148). Later studies assigned this killing to CD4+CD25+ 
Tregs (149, 150) as well as to activated effector T cells, defined 
as Treg-depleted CD4+CD25− T cells or cloned antigen-specific 
CD4+ T cells (39, 148). A recent study showed that CD4+ (and 
CD8+) T cells from the BAL fluid of C57BL/6 mice express 
FASL and that these T cell populations can induce apoptosis 
in autologous alveolar macrophages. Although apoptosis by 
CD8+ T cells was more prevalent, killing by CD4+ T cells was 
observed (151). Evidence from our lab has shown that activated 
CD4+CD25− effector T (Teff) cells upregulate FASL, and upon 
coculture with human monocytes, activate, and then kill the 
monocytes in a FAS/FASL-dependent manner (39). Blocking 
the FAS/FASL interactions reduced monocyte apoptosis but 
did not affect the expression of FAS, CD14, or HLA-DR on the 
monocytes, indicating that the monocytes still became activated 
by the T cells. T cells may also kill monocytes/macrophages in 
a FAS-independent mechanism, as TRAIL and TWEAK death 
receptor pathways have been implicated in macrophage killing 
by CD4+ T cells (152).
Modulation of Monocyte/Macrophage 
Function by CD4+ Regulatory T Cells
Regulatory T cells are generally defined as CD4+CD25+CD127low 
FOXP3+ cells. The suppressive effects of Tregs on immune cells 
have been documented widely, in particular on cells from the 
adaptive immune system (CD4+ and CD8+ T cells) [reviewed 
in Ref. (153–155)]. Tregs can employ several mechanisms of 
suppression including release of the inhibitory cytokines IL-10 
and TGFβ, cytolysis via release of granzymes A and B, metabolic 
disruption via IL-2 consumption or through degradation of ATP 
to AMP/ADP, and eventually adenosine via the ectonucleotidases 
CD39 and CD73. There is ample evidence that Tregs can also 
interact directly with antigen-presenting cells, including mono-
cytes and macrophages [reviewed in Ref. (156)].
Modulation of monocyte function in vitro has been shown by 
a series of experiments from our lab. The first study compared 
monocytes from the peripheral blood of healthy human donors 
cultured alone, or cocultured with autologous effector T cells or 
Tregs. Coculture with anti-CD3 mAb and effector T cells induced 
an activated phenotype in the monocytes, with increased levels 
of CD80, CD40, and HLA II compared to monocytes cultured 
alone (157). When monocytes were cocultured with Tregs, levels 
of CD40, CD80, and HLA II on monocytes were not increased 
compared to the monocyte only culture, while CD86 expression 
was significantly reduced. These monocytes were impaired in 
their ability to induce T cell proliferation in subsequent T cell 
stimulation assays. In a following study, we demonstrated that 
upon coculture with Tregs, monocytes expressed increased 
levels of the mannose receptor CD206 and hemoglobin/hap-
toglobin scavenger receptor CD163 (158), markers which are 
associated with M2-like macrophages (127, 129). In support of 
November 2015 | Volume 6 | Article 5719
Roberts et al. Monocyte/T Cell Interplay in RA
Frontiers in Immunology | www.frontiersin.org
these phenotypic changes, we found that phagocytosis of FITC-
zymosan/latex beads was increased in Treg cocultured monocytes, 
although the number of monocytes that phagocytosed the beads 
did not change significantly (158). Furthermore, LPS-induced 
NFκB activation and secretion of TNFα and IL-6 were decreased 
in monocytes cocultured with Tregs, compared to those cultured 
alone or with effector T cells. Using flow cytometry, it was shown 
that the frequencies of LPS-induced IL-6 and TNFα expressing 
monocytes were also reduced upon coculture with Tregs as 
compared to monocytes cultured alone or with Teffs, indicating 
that the observed differences in cytokine secretion were due to 
changes within cytokine-expressing monocytes (39). This was not 
due to cell death, as in contrast to CD4+CD25− Teff, Tregs did not 
kill the monocytes upon interaction (39). The decreased produc-
tion of IL-6 and TNFα in response to LPS was still observed when 
monocytes were re-purified after coculture (158), indicating that 
Tregs imprint changes in the monocytes, suggestive of “trained 
immunity.” Immune memory has traditionally been associated 
with cells of the adaptive immune system; recently, the term 
“trained immunity” has been used to define the memory capacity 
within innate immune cells (159). Induction of trained immunity 
in monocytes has been shown in studies whereby exposure to 
beta-glucan led to epigenetic modifications in monocytes, result-
ing in phenotypic changes and altered function (160). Further 
investigation is required to determine whether the effects of Tregs 
on monocytes are reflective of a state of “trained immunity” in 
these cells.
The modulation of monocytes by Tregs was shown to be 
dependent in part on soluble factors (IL-10 and IL-4/IL-13) 
as well as cell-contact (158). A different group showed that 
cocultures of human CD14+ monocytes with sorted Tregs led 
to increased levels of secreted IL-10 and higher levels of B7-H4 
receptor on the monocytes. These monocytes were less capable 
of stimulating a T cell proliferative response, which was due in 
part to the expression of IL-10 and B7-H4 (161). Notably, work 
from the same group showed that the expression of B7-H4 was a 
marker for immunosuppressive tumor-associated macrophages 
in ovarian carcinoma (162), and that the presence of Tregs and 
macrophage-associated B7-H4 at the tumor site was negatively 
associated with patient outcome (163, 164). Together, these data 
indicate that modulation of monocytes and macrophages by 
Tregs may have functional consequences in disease.
Modulation of macrophage function by Tregs has also been 
shown in  vivo. Adoptive transfer of syngeneic CD4+CD25+ 
Tregs into the peritoneal cavity of SCID mice revealed both 
phenotypic and functional changes in peritoneal macrophages 
(165). In this study, SCID mice were adoptively transferred with 
either no T cells, CD4+CD25+ Tregs, CD4+CD25− T cells, or both 
CD4+CD25+ Treg and CD4+CD25− T cells at a 1:1 ratio. The per-
centages of F4/80+ macrophages expressing CD54, CD80, CD86, 
or I-Ad were significantly decreased in SCID mice transferred 
with Tregs compared to the control mice and were increased in 
mice receiving CD4+CD25− T cells. The latter increase was inhib-
ited when both T cell types were cotransferred. The group also 
showed that macrophages from mice transferred with Tregs had 
an enhanced phagocytic capacity compared to those transferred 
with CD4+CD25− T cells or no T cells. The enhanced phagocytic 
capacity was reversed by transfer with both cell types. Upon LPS 
stimulation, macrophages from SCID mice transferred with 
CD4+CD25+ Treg cells produced more IL-10 and less IL-12 than 
those from mice transferred with CD4+CD25− T cells. The mac-
rophages from mice receiving Tregs were also impaired in their 
antigen-presenting capacity and showed higher arginase activity 
and lower nitric oxide production compared to those from mice 
transferred with CD4+CD25− T cells or no T cells. Together, this 
work suggests that Tregs modulate macrophages toward an “M2” 
phenotype, with the functional and phenotypic characteristics of 
the modulated cells closely resembling those seen in the previ-
ously mentioned in vitro studies of human Tregs and monocytes.
Figure  2 summarizes existing evidence on the cellular and 
molecular mechanisms via which CD4+ effector vs. regulatory T 
cell subsets can affect the phenotype or function of monocytes 
and macrophages. As indicated in Figure 1, since much of the 
reported evidence comes from in  vitro studies, some caution 
should be exerted when extrapolating these findings to an in vivo 
situation.
DYSReGULATeD MONOCYTe/
MACROPHAGe HOMeOSTASiS iN THe 
RHeUMATOiD JOiNT
The abundance of CD14+/CD68+ monocytes/macrophages in the 
rheumatoid joint suggests that these cells are recruited at a high 
rate, are long-lived or proliferative, and/or resistant to apoptosis. 
Evidence exists to support all these scenarios. Chemokines 
involved in monocyte recruitment, such as CCL2/MCP-1, CCL3/
MIP-1α, and CCL5/RANTES, are readily detectable at the site 
of inflammation (96, 166), and blood monocytes from patients 
with RA express the corresponding chemokine receptors CCR1, 
CCR2, CCR3, and CCR5 (15). One study investigated the migra-
tion of labeled autologous CD14+ blood monocytes, isolated by 
CliniMACS procedure, in RA patients using single photon emis-
sion computer tomography. A very small but specific fraction 
of 0.003% of re-infused monocytes was found to migrate to the 
inflamed joints, being detectable within 1 h after re-infusion (167). 
Interestingly, monocyte influx into the inflamed joint was not 
altered early after anti-TNF treatment (2 weeks post-treatment) 
even though disease activity was significantly reduced (168). The 
authors concluded that monocytes migrate continuously into 
the inflamed synovial tissue of RA, but at a slow macrophage-
replacement rate, and that the rapid decrease in synovial mac-
rophage numbers observed after anti-TNF treatment (23) cannot 
be explained by an immediate effect on monocyte influx.
Another contributing factor to the persistently high mono-
cyte/macrophage presence in the rheumatoid joint is apoptosis 
resistance. Both RA peripheral blood monocytes and RA synovial 
monocytes/macrophages have been shown to be resistant to 
spontaneous cell death, agonistic Fas-antibody induced apopto-
sis, or responder T cell-mediated killing (28, 39, 40). Proposed 
underlying mechanisms include the enhanced expression of 
antiapoptotic molecules, such as FLIP and Mcl-1 in RA synovial 
FiGURe 2 | Proposed cellular and molecular mechanisms via which CD4+ T cell subsets can polarize or modulate monocyte/macrophage function. 
(A) The prototypical Th1 cytokine IFNγ can polarize monocytes to an “M1” phenotype, promoting proinflammatory cytokine release, reactive oxygen species (ROS) 
production, and metabolism of arginine to nitric oxide [reviewed in Ref. (125, 127)]. (B) Prototypical Th2 cytokines IL-4 and IL-13 can polarize monocytes to an “M2” 
phenotype, characterized by expression of anti-inflammatory cytokines such as IL-10, expression of CD206, increased phagocytosis, and metabolism of arginine to 
orthonine and polyamine intermediates [reviewed in Ref. (125, 127)]. (C) CD4+CD25+ Tregs have also been shown to induce an alternatively activated or anti-
inflammatory phenotype in monocytes in a cell-contact and soluble factor (IL-4, IL-13, and IL-10) dependent manner leading to reduced IL-6 and TNFα production, 
decreased NFκB activation and increased expression of IL-10, CD163, and B7-H4 (157, 158, 164, 165). (D) The prototypical Th17-associated cytokine IL-17 has 
been shown to increase levels of IL-1β, TNFα, and IL-6 released by macrophages (131, 132). IL-17 has also been suggested to be chemotactic for monocytes via 
ligation of IL-17RA/RC (133). (e) Evidence shows that activated CD4+CD25− T cells can activate but also induce apoptosis in monocytes/macrophages. Both FAS/
FASL- and TRAIL/TWEAK-dependent mechanisms have been proposed (39, 147, 148, 151, 152). (F) Activated RANKL-expressing Teff can drive osteoclast 
formation from monocytes when cultured in the presence of M-CSF (140). Th17-associated cytokines can upregulate RANKL on RA fibroblast-like synoviocytes and 
also directly induce monocyte-to-osteoclast differentiation (142, 143), while IFNγ has been shown to suppress osteoclast formation (141).
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tissue (169, 170), the reduced expression of the proapoptotic Bcl-2 
homology 3 (BH3)-only protein Bim (171), the increased produc-
tion of TNFα and IL-1 which have antiapoptotic effects (172), and 
the increased presence of Tregs in the RA joint (173), which do 
not exert apoptotic effects on monocytes (39). Incubation with 
the anti-TNF drugs infliximab or adalimumab has been shown to 
increase apoptosis in healthy or RA peripheral blood monocytes, 
lending support to the role of TNF in regulating this process 
(28, 174). Conversely, defects in apoptosis pathway-associated 
molecules, such as occur in Fas-deficient (lpr/lpr) mice, lead to an 
increase in the number of circulating monocytes and an increase 
in the proinflammatory activity of peritoneal macrophages and 
the development of systemic autoimmune disease including 
lupus-like disease and inflammatory arthritis (175). A recent 
study showed that selective loss of Fas in myeloid cells was suf-
ficient to induce SLE-like disease in mice (176). Together, these 
data illustrate that a dysregulation in monocyte/macrophage 
homeostasis may be an important contributing factor to chronic 
inflammatory joint disease.
In addition, recent advances in genetics have revealed an 
increasing number of susceptibility loci for RA (177), several of 
which may have relevance to monocyte/macrophage function or 
homeostasis, e.g., CD40, TNFAIP3, IRAK1, TRAF1/TRAF6, IRF5 
(178), and RBPJ (179). Future functional genomic studies may 
elucidate the exact role of these genes in RA and in monocytes/
macrophages in particular.
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Although knowledge regarding the phenotype and function 
of synovial macrophages is continuing to grow, it is much less 
clear what the origin of these cells is. Fate-mapping experiments 
in mice demonstrate that tissue-resident yolk sac-derived mac-
rophages develop in a Myb-independent manner and can persist 
in adult mice independently of hematopoietic stem cells (180, 
181). However, other work suggests that Myb-dependent fetal 
liver-derived monocytes also contribute to the pool of tissue-
resident cells (182, 183). In addition, although self-renewing 
tissue-resident macrophage populations have been described 
(182–185), evidence suggests that recruited blood monocytes 
may play a role in replenishing the macrophage population 
during inflammation (186–188). The investigation of the origin 
and homeostasis of tissue macrophages remains an active field 
of research, and future work may be able to determine whether 
RA synovial macrophages are equivalent to these long-lived 
cells, or are continuously replaced by newly recruited peripheral 
monocytes.
TARGeTiNG MONOCYTeS/
MACROPHAGeS iN RA
The findings discussed in this review indicate that selective tar-
geting of monocytes/macrophages could have therapeutic benefit 
in RA [also reviewed in Ref. (5)]. This is supported by older data 
showing that treatment of severe RA with leukapheresis effi-
ciently removed blood monocytes concomitant with a clinical 
response (189), and that depleting CCR2+ monocytes using 
anti-CCR2 mAb could ameliorate collagen-induced arthritis, 
although the effects were dependent on the dose of mAb used 
(190). In  vitro, selective elimination of human macrophages 
using toxin-conjugated Abs against CD64 resulted in reduced T 
cell proliferation and reduced TNFα production by synovial fluid 
mononuclear cells and synovial tissue explants (191). Bim-BH3 
mimetic therapy could induce apoptosis in myeloid cells and 
suppress clinical severity of experimental arthritis (171). siRNA-
based therapeutic approaches are also being developed in order 
to selectively target certain genes or pathways (192).
Additionally, given the importance of T cell-monocyte 
crosstalk in promoting inflammation (17, 137, 193), approaches 
that target T cell-monocyte interactions may have therapeutic 
benefit. Indeed, this may be one way via which drugs like 
abatacept (CTLA4-Ig) exert their clinical effect. Previously 
underappreciated mechanisms of existing therapeutics may 
contribute to their efficacy by (in)directly targeting monocytes/
macrophages. For example, multiple studies have shown that 
blockade of IL-6 signaling via monoclonal antibody to the IL-6 
receptor (tocilizumab) can boost Treg frequencies (194–198), 
but additional mechanisms of action may include reduction in 
CD69+CD14+ and CD16+CD14+ monocyte frequencies (197), 
induction of monocyte apoptosis, and inhibition of monocytic 
IL-6 mRNA expression (199). Despite the widespread uptake 
and high efficacy of TNFα inhibitor drugs in RA, the underlying 
mechanisms of action are not firmly established [reviewed in Ref. 
(200)]. TNF inhibitor drugs block signaling of the key monocyte/
macrophage-derived cytokine TNFα but can also reduce produc-
tion of other proinflammatory mediators, such as IL-1β, GM-CSF, 
IL-6 and IL-8, in synovial membrane (201–203). Furthermore, it 
has been reported that Treg function can be restored or enhanced 
following TNFα inhibitor therapy (111, 204), and we and oth-
ers recently demonstrated that TNFα blockade in cocultures of 
antigen presenting cells and CD4+ T cells favors development of 
an immunoregulatory phenotype in effector CD4+ T cells by pro-
moting expression of IL-10 (205, 206). We showed that following 
TNF blockade, a significant proportion of IL-17 expressing CD4+ 
T cells coexpressed IL-10, which was biologically active and was 
able to modulate the phenotype of monocytes leading to reduced 
HLA-DR and CD40 expression and increased CD163 expression 
(205). Another postulated mechanism of anti-TNF drugs is via 
interaction with tmTNFα (28, 207). It was recently shown that 
production of cytokines and decoy receptors triggered by mono-
cyte tmTNF crosslinking might provide a prognostic parameter 
for predicting therapeutic response to etanercept, suggesting a 
role for monocytic reverse signaling in the clinical efficacy of TNF 
inhibitors (208).
As previously discussed, monocytes/macrophages contrib-
ute to bone erosion in RA via differentiation into osteoclasts. 
Inhibiting osteoclastogenesis therefore presents a key target for 
therapeutic intervention, since the presence of bone erosions 
represents irreversible structural damage, associated with loss 
of joint function and poor quality of life. TNFα inhibitor drugs 
inhibit radiological progression, even in the absence of clinical 
response, via direct inhibitory effects on osteoclast differentiation 
and activity (209). Binding of CTLA4 to CD80/86 on monocytes 
provides a potent signal to inhibit differentiation into osteoclasts; 
accordingly abatacept was recently shown to inhibit osteoclas-
togenesis in human peripheral monocytes (210). A phase II clinical 
trial found that twice-yearly injections of the anti-RANKL drug 
denosumab inhibited progression of bone erosion in RA patients 
with active erosive disease but demonstrated no effect on disease 
activity (211). Similarly, RANKL knockout mice are protected 
from bone erosion in a serum transfer model of arthritis but dis-
play inflammation that is clinically and histologically similar to 
wild type (212). These data suggest that targeting osteoclastogen-
esis may have the potential to reduce structural joint damage, but 
that RANKL blockade alone may be ineffective at controlling the 
underlying inflammatory process. As an alternative strategy to 
inhibit osteoclastogenesis, targeting M-CSF receptor (M-CSFR, 
also known as CSF1R, c-FMS, and CD115) has been shown in 
various animal models of autoimmune arthritis to reduce both 
joint inflammation and bone destruction (213–216) However, 
in some models, while bone erosion is reduced, inflammation is 
unaffected by M-CSFR antibody blockade (215) or c-FMS kinase 
inhibition (217). Effective targeting of the M-CSFR pathway in 
RA may require blocking signaling of both its ligands, M-CSF and 
IL-34. Several clinical trials are currently investigating antibodies 
or small molecules targeting the M-CSFR pathway in RA and 
other indications [reviewed in Ref. (218)].
Epigenetic control of immune-mediated processes is a 
growing field of study with the potential to unveil mechanisms 
of immune regulation which may be amenable to therapeutic 
FiGURe 3 | Therapeutic strategies to target monocytes/macrophages in RA. Several novel strategies for drug intervention in RA, as well as currently used 
therapeutics, have potential mechanisms of action that target monocyte/macrophages or their interaction with CD4+ T cells. Selected therapies are presented with 
particular reference to their reported effects on monocyte/macrophage function and CD4+ T cell interactions. Red and green lines indicate inhibition and promotion, 
respectively, while dashed lines indicate novel or putative mechanisms that may require further confirmation. TNF inhibitor drugs block signaling of the key 
monocyte/macrophage-derived cytokine TNFα and have been shown to promote increased IL-10 expression in CD4+ T cells (205, 206), enhanced or restored Treg 
function (111, 204) and anti-osteoclast effects (209), and may also exert anti-inflammatory/proapoptotic effects on monocytes via “reverse signaling” through 
tmTNFα (28, 208). Blockade of IL-6 signaling (via monoclonal antibody to the IL-6 receptor, tocilizumab) reportedly boosts Treg frequencies (194–198) and has been 
suggested to inhibit monocyte IL-6 mRNA expression and induce monocyte apoptosis (199). Another widely used RA drug, abatacept (CTLA4-Ig), targets the 
interaction between monocytes and T cells, specifically impairing T cell costimulatory signals via CD80/CD86. Abatacept has also been reported to inhibit monocyte 
differentiation into osteoclasts (210). Several other approaches are currently under development to specifically target osteoclastogenesis, including blockade of 
RANKL (211) or M-CSF (218). Janus Kinase (JAK) inhibitors (Jakinibs) target JAK/STAT-mediated cytokine signaling in T cells and possibly also in macrophages 
(231, 232) and may reduce monocyte-derived DC costimulatory capacity (230). Bromodomain and extraterminal (BET) inhibitors are also under consideration for the 
treatment of inflammatory disease. Efficacy has been shown in collagen-induced arthritis where BET inhibition reduced Th17 responses (221). Reduced transcription 
of proinflammatory genes has been described in human monocytes (222) and mouse macrophages (219, 220) following in vitro exposure to BET inhibitors.
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intervention. Bromodomain and extraterminal (BET) inhibitors 
have recently emerged as a promising approach to treat cancer 
but are also being investigated in the context of inflammatory 
disease. Blocking the recruitment of BET proteins to acetylated 
histones inhibits BET-mediated transcriptional activity. BET 
inhibitors have been shown to suppress expression of proin-
flammatory cytokines and chemokines in LPS-stimulated bone 
marrow-derived macrophages in vitro (219, 220). In vivo BET 
inhibition resulted in reduced Th17 differentiation, suppres-
sion of established Th17 responses, and protection against 
pathology in collagen-induced arthritis (221). A recent study 
found that BET inhibition suppressed cytokine-induced 
transcription in primary human monocytes in a gene-specific 
manner, without affecting JAK-STAT signaling. Instead, BET 
inhibition reduced recruitment of transcriptional machinery 
to the CXCL10 promoter and an upstream enhancer (222). 
In future studies, global approaches, such as genome-wide 
profiling, may identify additional functional pathways that 
are amenable to BET-mediated transcriptional regulation in 
monocytes/macrophages.
Additional therapeutic approaches under development for 
RA include proteasome inhibitors, such as bortezomib (223). 
Conflicting data on the effects of bortezomib on bone resorp-
tion are reported in different animal models of RA (224, 225). 
In human cells, bortezomib appears to inhibit osteoclastogenesis 
(226, 227). Selective inhibition of a subunit of the immunoprotea-
some (a class of proteasome primarily found in monocytes and 
lymphocytes) was shown to inhibit production of IL-23, TNFα, 
and IL-6 by LPS-activated monocytes and to reduce IFNγ and 
IL-2 production from anti-CD3/CD28-activated T cells (228). 
These data were generated using cells from healthy donors, 
but similar results were observed using PBMC from three RA 
patients. In mouse models of RA, immunoproteasome inhibition 
ameliorated disease and also blocked IL-23 production from 
activated monocytes.
Protein kinase inhibitors are another class of small molecule 
therapeutics gaining attention for the treatment of immune-medi-
ated diseases. Tofacitinib, the first Janus kinase (JAK) inhibitor to 
be developed for RA was approved by the FDA in 2012. To date, 
most studies have focused on the effects of JAK inhibition in T cells 
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with relatively few data on the consequences in monocytes/mac-
rophages. A recent report found that tofacitinib did not directly 
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LPS-induced cytokine production (232). These data indicate that 
JAK inhibitor drugs do have the capacity to modulate monocyte/
macrophage function, but the exact cellular mechanisms that 
mediate the clinical efficacy of these therapeutics are still under 
investigation.
Figure 3 shows an overview of how drugs currently used to 
treat RA, as well as therapeutics under development, may target 
monocytes/macrophages or their interaction with CD4+ T cells, 
to intervene in the underlying inflammatory and erosive disease 
processes.
SUMMARiZiNG CONCLUSiON
In summary, there is strong evidence for a contributing role of 
both monocytes/macrophages and CD4+ T cells in RA. In addi-
tion to directly promoting local inflammation by secreting proin-
flammatory mediators, synovial monocytes/macrophages secrete 
chemokines that can attract and maintain CD4+ T cells in the 
joint. A growing evidence base suggests that activated (subsets of) 
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Th1/Th17. Through their cytokine production monocytes/
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regulatory CD4+ T cells. Conversely, CD4+ effector T cells can 
activate, polarize, as well as kill monocytes and macrophages 
and may influence monocyte chemotaxis, while CD4+ Tregs can 
exert immunomodulatory effects on these cells, thereby enhanc-
ing their survival and inducing an anti-inflammatory state in 
monocytes/macrophages. To inform future research, refining the 
phenotypic characterization of monocyte/macrophage subpopu-
lations by validating additional phenotypic markers would facili-
tate further investigation of their involvement in inflammatory 
conditions, such as RA. Given that the complexity of monocyte/
macrophage phenotypes is not well understood or necessarily 
reflected in animal models or immortalized cell lines, studies 
of human primary monocytes and macrophages are essential to 
understand the contribution of these cells to RA pathogenesis. 
Improved knowledge regarding the origin of synovial monocyte/
macrophages could lead to a better understanding of the roles 
of tissue-resident macrophages in the RA joint. Finally, further 
investigation into the direct interactions between tissue-resident 
CD4+ T cell subsets and macrophages may elucidate how effector 
T cell responses are generated in situ as well as how macrophage 
responses can be regulated differentially by CD4+ effector and 
Tregs. Several existing RA therapeutics are known to impact on 
the crosstalk between monocytes and CD4+ T cells. An increased 
understanding of how the interactions between these cell types 
may contribute to immune pathology will benefit the develop-
ment of new and improved therapeutic strategies.
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